National Research Corp

National Research Corp(NRC)股票分析

$22.450

+0.532 (+2.37%)收盘时

Loading chart…
最高
22.600
开盘
21.850
成交量加权均价
22.19
成交量
93.89K
市值
548.94M
最低
21.525
成交额
2.08M
企业价值/息税折旧摊销前利润(TTM)
70.36

NRC Health, formerly National Research Corporation, provides healthcare experience improvement solutions. The Company is focused on improving the challenged healthcare ecosystem with stakeholder experience insights, market intelligence data, and software tools that enable health systems to improve patient outcomes and hospital operations. Its solutions consist of four solution categories: Patient Experience, Consumer Experience, Employee Experience, and Market Experience. The Company's portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty.

AI 分析 of National Research Corp (NRC)

买入

National Research Corp (NRC) is a good buy right now due to its strong recent performance, with a current price of $21.93 and a year-to-date change of +21.63%. The company has shown resilience with a gross margin of 56.41% and a forward P/E ratio of 17.21, indicating potential for future earnings growth. However, the main risk is its high debt-to-equity ratio of 1374.68%, which could impact financial stability if not managed properly.

估值指标

National Research Corp(NRC)当前预期市盈率为 17.21,5 年平均预期市盈率为 26.03。

预期市盈率

合理
5 年均值 P/E
26.03
当前P/E
17.21
高估
36.07
低估
15.99

预期 EV/EBITDA

严重高估
5 年均值 EV/EBITDA
19.71
当前EV/EBITDA
70.36
高估
34.42
低估
5.00

预期市销率

低估
5 年均值 P/S
5.74
当前P/S
3.21
高估
8.11
低估
3.36

事件时间线

2026-08-12 (ET)

16:30:00

Resideo Appoints Shane Harrison as CFO

2026-05-19 (ET)

09:20:00

NRC Health Introduces New AI Features to Enhance Healthcare Interactions

2026-04-07 (ET)

09:20:00

NRC Health Expands Partnership with Ann & Robert H. Lurie Children's Hospital

2026-03-09 (ET)

16:40:00

NRC Health Authorizes Stock Repurchase Program Up to $60M

2026-03-04 (ET)

16:30:00

National Research Corporation TRCV Surpasses $152 Million

资讯

NRC 常见问题 —— 由 Alphio AI 解答

NRC Health, formerly National Research Corporation, provides healthcare experience improvement solutions. The Company is focused on improving the challenged healthcare ecosystem with stakeholder experience insights, market intelligence data, and software tools that enable health systems to improve patient outcomes and hospital operations. Its solutions consist of four solution categories: Patient Experience, Consumer Experience, Employee Experience, and Market Experience. The Company's portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty. It operates in the Industrials sector (SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH industry).

National Research Corp (NRC) is a good buy right now due to its strong recent performance, with a current price of $21.93 and a year-to-date change of +21.63%. The company has shown resilience with a gross margin of 56.41% and a forward P/E ratio of 17.21, indicating potential for future earnings growth. However, the main risk is its high debt-to-equity ratio of 1374.68%, which could impact financial stability if not managed properly.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易